Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age

Main Article Content

Linda Stein Gold
Henry Ford Hospital, Detroit, MI

Hilary Baldwin
The Acne Treatment and Research Center, Brooklyn, NY and The Robert Wood Johnson University Hospital, New Brunswick, NJ

Fran Cook-Bolden
Fran E. Cook-Bolden, MD, PLLC and Department of Dermatology, Mount Sinai Hospital Center, New York, NY

Lawrence Green
Department of Dermatology, George Washington University School of Medicine, Washington, DC

Glynis Ablon
Ablon Skin Institute & Research Center, Manhattan Beach, CA

Neil Sadick
Department of Dermatology, Weill Cornell Medical College, New York, NY and Sadick Dermatology, New York, NY

Jonathan Weiss
Georgia Dermatology Partners and Gwinnett Clinical Research Center, Inc., Snellville, GA

Eric Guenin
Ortho Dermatologics*, Bridgewater, NJ *Ortho Dermatologics is a division of Bausch Health US, LLC.

Keywords

Acne Vulgaris, Topical Retinoid, Lotion, Efficacy, Safety, Female Patients

Abstract

Abstract not available.

References

1. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945-973.e933.

2. Skroza N, et al. J Clin Aesthet Dermatol. 2018;11(1):21-25.

3. Collier CN, et al. J Am Acad Dermatol. 2008;58(1):56-59.

4. Tan JK, et al. J Cutan Med Surg. 2008;12(5):235-242.

5. Tanghetti EA et al. J Drugs Dermatol. 2020;19(3):272-279

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.23

Article Details

How to Cite
[1]
Stein Gold, L., Baldwin, H., Cook-Bolden, F., Green, L., Ablon, G., Sadick, N., Weiss, J. and Guenin, E. 2021. Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s23. DOI:https://doi.org/10.25251/skin.5.supp.23.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>